Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Prof. Dr. Ulrike Stein CV CV Prof. Dr. rer. nat. habil. Ulrike Susanne Stein Place of birth: Family status: Naumburg/Saale, Germany Married, 2 children (Philipp Maximilian *1986; Luise Theresa *2005) Address, work: Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine Head: Translational Oncology of Solid Tumors Robert-Rössle-Straße 10, 13125 Berlin, Germany +49 - 30 - 9406 3432, +49 - 30 - 9406 2780, [email protected] Tel, Fax, Email: Occupational Carrier 1979 – 1984 Diploma Student, Biochemistry, Martin-Luther-Universitäy, Halle, Germany 1984 – 1991 PhD Student (and maternal leave) Central Institute for Cancer Research, Depts Virology and Carcinogenesis, Berlin 1987 – 1991 Postgraduate Education: Specialist for Medicinal Biochemistry, Academy for Physicians Education, Berlin 1989 Research Stay, one month, Oncological Institute, St. Petersburg, Russia 1990 European Summer School, one month, UICC, Lyon, Frankreich Fellowship from UICC and Boehringer Ingelheim-Foundation, Stuttgart 1991 PhD in Biochemistry, Dr. rer. nat., Humboldt-University, Berlin 1992 – 1993 Post-Doc, Max-Delbrück-Center for Molecular Medicine, Berlin, Dept. Exp. Tumor Therapy 1994 – 1995 Research Stay, National Cancer Institute, Frederick, MD, USA Feodor-Lynen-fellowship of the Alexander von Humboldt-Foundation, Bonn, and of the Fogarty International Center NIH, Bethesda, MD, USA 1996 – 2000 Head: Multidrug resistance Max-Delbrück-Center for Molecular Medicine, in Research Group Surgical Oncology 1996 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Fellowship Stifterverbandes für die Deutsche Wissenschaft, Essen 1997 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn 1998 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn 2000 - 2006 Head: Tumor metastasis and therapy response Robert-Rössle-Hospital, Charité Universitätsmedizin Berlin, in Research Group Surgical Oncology 2001 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Fellowship Science Applications International Corporation, Frederick, MD, USA 2003 Habilitation in Biochemistry, Charité Universitätsmedizin Berlin 2003 Venia legendi for Biochemistry, Privat-Dozentin, Charité Universitätsmedizin Berlin 2003 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Fellowship Science Applications International Corporation, Frederick, MD, USA 1 Prof. Dr. Ulrike Stein CV 2007 Head: Tumor metastasis and therapy response Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine, in Research Group Surgical Oncology 2007 Research Stay, one month, National Cancer Institute, Frederick, MD, USA Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn 2009 Professorship, Charité Universitätsmedizin Berlin 2011 Research Stay, one month, National Cancer Institute, Frederick, MD, USA 2013 Head: Translational oncology of solid tumors Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine Scientific awards, selected 2014 Felix Burda Award (Foundation for Prevention and Research of Colorectal Cancer), Berlin 2011 Award 16. World Congress on Advances in Oncology, Rhodos, Greece 2010 Award Berlin-Brandenburgische Akademie der Wissenschaften, funded by the Monika-Kutzner-Foundation for Cancer Research, Potsdam 2009 Wissenschaftspreis (Science Award) of the German Cancer Society (AIO Arbeitsgemeinschaft Internistische Onkologie) – preclinical/translational part, Berlin 2009 Award 15. International AEK (Arbeitsgemeinschaft Experimentelle Krebsforschung in the German Cancer Society) Cancer Meeting, Berlin 2005 Award Epithelial Mesenchymal Transition Conference, Vancouver, BC, Canada 2000 Award 24. German Cancer Congress (Poster) Berlin 1996 Award 22. German Cancer Congress (Poster) Berlin 1994 Award 21. German Cancer Congress (Poster) Berlin 1989 Award of the President of the Academy of Sciences, Halle 1988 Young Researcher Award, Academy of Sciences, Berlin 1985 Young Researcher Award, Academy of Sciences, Berlin Berlin, March 3 2016 2 Prof. Dr. Ulrike Stein Publication list Publication list Impact Factors per respective year (for 2015: IF 2014) ISI Web of Science (3.3.2016): Hirsch (h) – Index: 31 Personal Scientific Citations (PSI) - Index: 2,653 ResearchGate RG (3.3.2016): RG Score: 41.97 RG Publications: 171 RG Reads: 4.07 k RG Citations: 3,206 RG Impact Points: 735.16 Impact Factors, total: 493.994 Original articles and reviews, no published abstracts Total First author Last author Co-author Original articles 439.972 147.272 122.557 170.143 Reviews 54.022 10.733 33.960 9.329 Publications, total: 134 Original articles, reviews, books and book chapters, no published abstracts Total First author Last author Co-author Original articles 92 27 24 41 Reviews 16 7 6 3 Books 4 0 4 0 Book chapters 22 6 7 9 Total First author Last author Co-author 185 126 42 18 Total First author Last author Co-author 189 49 80 60 Talks, total: 186 invited (US): 108 all Posters, total: 189 all 1 Prof. Dr. Ulrike Stein Publication list Original articles: 92 (IF 439.972) 2016 Lemos C, Hardt M, Juneja M, Voss C, Förster S, Jerchow B, Haider W, Bläker H, Stein U. MACC1 induces tumor progression in transgenic mice and colorectal cancer patients via increased pluripotency markers Nanog and Oct4. Clin Cancer Res. 2016 Jan 12. pii: clincanres.1425.2015. [Epub ahead of print] IF 8.722 2015 Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, Dahlmann M, Kobelt D, Walther W, Smith J, Schlag PM, Stein U. SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival. Oncogene. 2015 Dec 21. doi: 10.1038/onc.2015.451. [Epub ahead of print] IF 8.459 Walther W, Kobelt D, Bauer L, Aumann J, Stein U. Chemosensitization by diverging modulation by short- and long-term TNFalpha on ABCB1 expression and NFkB signaling in colon cancer. Int J Onc, 47: 2276-2285, 2015 IF 3.025 Lederer A, Herrmann P, Seehofer P, Dietel M, Pratschke J, Schlag PM, Stein U. MACC1 is an independent prognostic biomarker for survival in Klatskin tumor patients. Hepatology, 62:841-850, 2015 IF 11.055 Koelzer VH, Hermann P, Zlobec I, Karamitopoulou E, Lugli A, Stein U. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 for survival prognosis of colorectal cancer patients: a retrospective cohort study. BMC Cancer, 15:160, 2015 IF 3.362 Ilm K, Kemmner W, Osterland M, Koch G, Herrmann P, Schlag PM, Stein U. High MACC1 expression together with mutated KRAS G13 indicate high risk colorectal cancer. Mol Cancer, 14:38, 2015 IF 4.257 Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Stein U. Circulating MACC1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker. World J Gastroenterol, 21:333-341, 2015 IF 2.369 Medapati MR, Dahlmann M, Ghavami S, Pathak A, Lucman L, Hoang-Vu C, Stein U, Hombach-Klonisch S. RAGE mediates the pro-migratory response of extracellular S100A4 in human thyroid cancer cells. Thyroid, 25:514-527, 2015 IF 4.493 Hansen M, Forst B, Cremers N, Quagliata L, Ambartsumian N, Grum-Schwensen B, Klingelhöfer J, Abdul-Al A, Herrmann P, Osterland M, Stein U, Nielsen G, Scherer P, Lukanidin E, Grigorian M, Sleeman J. A link between inflammation and metastasis: Serum Amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 34:424-435, 2015 IF 8.459 2014 Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith J, Heizmann C, Schlag PM, Stein U. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget, 5:3220-3233, 2014 IF 6.359 2013 Hagemann C, Fuchs S, Monoranu CM, Herrmann P, Smith J, Hohmann T, Grabiec U, Kessler AF, Dehghani F, Löhr M, Ernestus RI, Vince GH, Stein U. Impact of MACC1 on human malignant glioma progression and unfavorable patients’ prognosis. Neuro-Oncol, 15:1696-1709, 2013 IF 5.286 Juneja M, Ilm K, Schlag PM, Stein U. Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol, 7:929-943, 2013 IF 5.937 Grabundzija I, Wang, J, Sebe A, Erdei Z, Kajdi R, Devaraj A, Steinemann D, Szuhai K, Stein U, Cantz T, Schambach A, Baum C, Izsvák Z, Sarkadi B, Ivics Z. Sleeping beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucl Acids Res 41:1829-1847, 2013 IF 8.808 2 Prof. Dr. Ulrike Stein Publication list 2012 Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KW, Schlag PM. Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS ONE, 7:e49249, 2012 IF 3.730 Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH, Walther W. Impact of mutant -catenin on ABCB1 expression and therapy response in colon cancer cells Br J Cancer, 106:1395-1405, 2012 IF 5.082 Nitsche U, Rosenberg R, Balmert A, Schuster T, Slotta-Huspenina J, Herrmann P, Bader FG, Friess H, Schlag PM, Stein U*, Janssen KP*, *contributed equally Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surgery, 256: 763-771, 2012 IF 6.329 Schmid F, Burock S, Klockmeier K, Schlag PM, Stein U. SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer. Mol Cancer, 2012 11:49, 2012 IF 5.134 Dahlmann M, Sack U, Herrmann P, Lemm M, Fichtner I, Schlag PM, Stein U. Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation. Oncotarget, 3: 783-797, 2012 IF 6.636 Pichorner A, Sack U, Kobelt D, Kelch I, Arlt F, Smith J, Walther W, Schlag PM, Stein U. In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis, 29: 573-583, 2012 IF 3.460 Neeb A, Wallbaum S, Novac N, Dukovic-Schulze S, Scholl I, Schreiber C, Schlag P, Moll J, Stein U, Sleeman JP. The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients. Oncogene 31:3796-3806, 2012 IF 7.357 Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I, Lemm M, Piontek J, Blasig IE, Stein U, Schlag PM. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3 and -4 overexpressing tumors. Gene Ther, 19:494-503, 2012 IF 4.321 2011 Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Schlag PM. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn, 13:189-198, 2011 IF 3.576 Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM. catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia, 13:131-144, 2011 IF 5.946 - Sack U, Walther W, Scudiero D, Selby M, Aumann J, Lemos C, Fichtner I, Schlag PM, Shoemaker RH, Stein U. S100A4-induced cell motility and metastasis is restricted by the Wnt/b-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell, 22:3344-3354, 2011 IF 4.942 Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH, Stein U. Novel effect of anti-helmintic niclosamide on S100A4-induced metastasis in colon cancer. J Natl Cancer Inst, 103:1018-1836, 2011 IF 13.757 Thiele W, Novac N, Mink S, Schreiber C, Plaumann D, Fritzmann J, Cremers N, Rothley M, Schwager C, Regiert T, Huber PE, Stein U, Schlag P, Moll J, Abdollahi A, Sleeman JP. Discovery of a novel tumour metastasis-promoting gene, NVM-1. J Pathol, 225:96-105, 2011 IF 6.318 2010 Jürchott K, Kuban R-J, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kielbasa SM, Ungethüm U, Lund P, Knösel K, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperleing S, Sers C, Royer H-D, Herzel H, Schäfer R. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. Plos Genetics, 6:e1001231(1-19), 2010 IF 9.543 3 Prof. Dr. Ulrike Stein Publication list Kobelt D, Aumann J, Fichtner I, Stein U, Schlag PM, Walther W. Activation of the CMV-IE promoter by hyperthermia in vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expresion. Mol Biotechnol 46:197-205, 2010 IF 2.091 Müller T, Stein U, Poletti A, Garzia L, Rothley M, Plaumann D, Thiele W, Bauer M, Galasso A, Schlag PM, Pankratz M, Zollo M, Sleeman JP. ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. Oncogene 29:2393-2403, 2010 IF 7.414 2009 Stein U, Smith J, Walther W, Arlt F. MACC1 controls Met – what a difference an Sp1 site makes. Cell Cycle, 8:2467-2469, 2009 IF 4.087 Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF/Met signaling, predicts colon cancer metastasis. Nature Med 15:59-67, 2009 IF 27.136 Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck F, Stein U, Fichtner I, Schlag PM, Birchmeier W. BAMBI links Wnt/β-catenin and TGFβ signaling in colorectal cancer metastasis. Gastroenterol 137:165-175, 2009 IF 12.899 2008 Stein U, Walther W, Stege A, Kaszubiak A, Fichtner I, Lage H. Complete in vivo reversal of the multidrug resistance (MDR) phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther 16:178-186, 2008 IF 5.970 Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A, Schleef M, Baier R, Stein U, Schlag PM. Nonviral intratumoral jet-injection gene transfer in metastatic melanoma and breast cancer: results of a phase I trial. Clin Cancer Res 14:7545-7553, 2008 IF 6.488 2007 Walther W, Arlt F, Fichtner I, Aumann J, Stein U, Schlag PM. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter regulated TNF- expression. Mol Cancer Ther 6:237-243, 2007 IF 4.800 2006 Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH. The metastasis-catenin / T-cell factor (TCF) signaling in colon cancer. Gastroenterol 131:1486-1500, 2006 IF 12.457 Walther W, Minow T, Martin R, Fichtner I, Schlag PM, Stein U. Uptake, biodistribution and time course of naked plasmid DNA trafficking after intratumoral in vivo jet-injection. Hum Gene Ther 17:611-624, 2006 IF 4.514 2005 Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM, Walther W. YB-1 facilitates basal and 5-fluorouracilinduced expression of major vault protein (MVP) gene. Oncogene 24:3606-3618, 2005 IF 6.872 Györffy B, Serra V, Jürchott K, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug resistant cell lines correlates with patient survival. Oncogene 24:7542-7551, 2005 IF 6.495 Walther W, Stein U, Fichtner I, Aumann J, Arlt F, Schlag PM. Nonviral jet-Injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol Ther 12:1176-1184, 2005 IF 5.443 Walther W, Stein U, Siegel R, Fichtner I, Schlag PM. Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved non-viral intratumoral in vivo gene transfer by jet-injection. J Gene Med 7:477-485, 2005 IF 3.699 2004 Walther W, Stein U, Fichtner I, Schlag PM. Low-volume jet-injection for efficient nonviral in vivo gene tranfer. Mol Biotechnol 28:121-128, 2004 IF 1.614 4 Prof. Dr. Ulrike Stein Publication list Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia 6:23-28, 2004 IF 4.377 Kupsakova I, Rybar A, Docolomansky P, Drobna Z, Stein U, Walther W, Barancik M, Breier A. Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study. Eur J Pharmaceut Science 21:283-293, 2004 IF 1.949 Knösel T, Yu Y, Stein U, Schwabe H, Schlüns K, Schlag PM, Dietel M, Petersen I. Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient‘s survival in advanced colorectal carcinomas. Dis Colon Rectum 47:70-77, 2004 IF 2.343 2003 Fitze G, Appelt H, König IR, Görgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, Schackert HK. Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genetics 12:3207-3214, 2003 IF 8.597 Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. Genetic imbalances with impact on survival in colorectal cancer patients. Histopathol 43:323-331, 2003 IF 2.952 Jürchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD. YB-1 as cell cycle regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278:27988-27996, 2003 IF 6.482 Walther W, Stein U, Voß C, Schmidt T, Schleef M, Schlag PM. Stability analysis for long-term storage of naked DNA: impact on non-viral in vivo gene transfer. Anal Biochem 318:230-235, 2003 IF 2.174 2002 Stein U, Jürchott K, Schläfke M, Hohenberger P. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 20:3282-3292, 2002 IF 10.864 Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M. Impact of BCRP/MXR, MRP1, and MDR1/Pglycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. Int J Cancer 97:751-760, 2002 IF 4.056 Knösel T, Yu Y, Stein U, Schwabe H, Schlüns K, Schlag PM, Dietel M, Petersen I. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metast 19:401-407, 2002 IF 2.080 Kowalski P, Stein U, Scheffer GL, Lage H. Moduation of the atypical multidrug–resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 9:579-586, 2002 IF 2.929 Walther W, Stein U, Fichtner I, Voß C, Schmidt T, Schleef M, Nellesen T, Schlag PM. Intratumoral low volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 21:105-115, 2002 IF 1.000 Drobna Z, Stein U, Walther W, Barancik M, Breier A. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdr1 gene expression in multidrug resistant mouse leukemic L1210/VCR cells Gen Physiol Biophys 21:103-109, 2002 IF 0.719 Knösel T, Petersen S, Schwabe H, Schlüns K, Stein U, Schlag PM, Dietel M, Petersen, I. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 440:187-194, 2002 IF 2.045 Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer 98:291-296, 2002 IF 4.056 5 Prof. Dr. Ulrike Stein Publication list 2001 Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 276:28562-28569, 2001 IF 7.258 Walther W, Stein U, Fichtner I, Schlag PM. In vivo gene transfer of naked DNA into xenotransplanted colon carcinoma by jetinjection. Langenbecks Arch Surgery 30:69-72, 2001 IF 1.538 Walther W, Stein U, Fichtner I, Malcherek L, Lemm M, Schlag PM. Nonviral in vivo gene delivery into tumors using a novel lowvolume jet-injection technology. Gene Ther 8:173-180, 2001 IF 5.893 2000 Lange C, Walther W, Schwabe H, Stein U. Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter. Biochem Biophys Res Comm 278:125-133, 2000 IF 3.055 Schwabe H, Stein U, Walther W. High-copy cDNA amplification of minimal total RNA quantities for gene expression analyses. Mol Biotechnol 14:165-172, 2000 IF 0.847 Cartier R, Ren SV, Walther W, Stein U, Lewis A, Schlag PM, Li M, Furth PA. In vivo gene transfer by low-volume jet injection. Anal Biochem 282:262-265, 2000 IF 1.976 Walther W, Stein U, Fichtner I, Alexander M, Shoemaker RH, Schlag PM. mdr1 promoter-driven tumor necrosis factor-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther 7:893-900, 2000 IF 4.151 1999 Stein U, Eder C, Karsten U, Haensch W, Walther W, Schlag PM. Gli gene expression in bone and soft tissue sarcomas of adult patients correlates with tumor grade. Cancer Res 59:1890-1895, 1999 IF 8.614 Stein U, Rau B, Wust P, Walther W, Schlag PM. Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. Int J Cancer 80:5-12, 1999 IF 3.545 Walther W, Stein U. Therapeutic genes for cancer gene therapy. Mol Biotechnol 13:21-28, 1999 IF 0.939 1998 Stein U, Walther W. Cytokine-mediated reversal of multidrug resistance. Cytotechnol 27:271-282, 1998 IF 0.616 Stein U, Walther W, Shoemaker RH, Schlag PM. IL-2 gene transfer for chemosensitization of multidrug-resistant human colon carcinoma cells. Adv Exp Med Biol 451:145-149, 1998 IF 0.360 Walther W, Stein U, Fichtner I, Naundorf H, Alexander M, Shoemaker RH, Schlag PM. In vivo evaluation of a drug-inducible vector system for the combined gene and chemotherapy of cancer. Adv Exp Med Biol 451:139-144, 1998 IF 0.360 1997 Stein U, Walther W, Lemm M, Naundorf H, Fichtner I. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 72:885-891, 1997 IF 3.362 Stein U, Walther W, Wendt J, Schild TA. In situ PCR/ RT-PCR by using fluorescence-labeled primers. BioTechniques 23:194-198, 1997 IF 1.946 Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Biother Cancer 1:53, 1997 IF 0.781 6 Prof. Dr. Ulrike Stein Publication list Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Tumor necrosis factormultidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 89:807-813, 1997 IF 11.430 Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 4:544-552, 1997 IF 7.410 1996 Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88:1383-1392, 1996 IF 10.328 Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 74:1384-1391, 1996 IF 3.666 Stein U, Walther W, Shoemaker RH. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. J Cancer Res Clin Oncol 122:275-282, 1996 IF 1.093 Stein U, Shoemaker RH., Schlag PM. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 32A:86-92, 1996IF 2.017 Walther W, Stein U. Targeted vectors for gene therapy of cancer and retroviral infections. Mol Biotechnol 6:267-286, 1996 IF 0.871 Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J Mol Med 74:379-392, 1996 IF 1.769 1995 Walther W, Stein U, Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer 61:832-839, 1995 IF 3.403 1994 Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 30A:1541-1545, 1994 IF 0.789 Wunderlich V, Stein U. Synergistic effect of tamoxifen and phorbol ester TPA on retrovirus synthesis in a human mammary carcinoma cell line. Int J Cancer 56:615-616, 1994 IF 3.276 Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 120:471-478, 1994 IF 1.654 Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M. Characterization of four drug-resistant P 388 sublines: resistance, sensitivity in vivo, resistance- and proliferation markers, immunogenicity. Anticancer Res 14:1995-2004, 1994 IF 1.049 Pfeil D, Bergmann J, Fichtner I, Stein U, Hentschel M, Rothe I, Goan SR. Multidrug resistance of murine leukemia cells characterization and correlation to cytochrome P-450 dependent activities, cytosolic calcium, and cell cycle state. Anticancer Res 14:571-576, 1994 IF 1.049 Walther W, Stein U, Eder C. RNA analysis using miniprep RNA in RT-PCR. BioTechniques 17:674-675, 1994 IF 1.946 1993 Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients. Eur J Cancer 29A:1979-1981, 1993 IF 0.789 7 Prof. Dr. Ulrike Stein Publication list Walther W, Stein U, Uckert W. Rapid method of total RNA mini-preparation from eucaryotic cells. Nucl Acids Res 21:1682, 1993IF 4.488 1992 Stein U, Wunderlich V, Uckert W. Inhibition of the TPA-induction of simian sarcoma virus by an antisense v-jun oncogene. Arch Geschwulstforsch 2:163-169, 1991 IF 0.900 1987 Uckert W, Wunderlich V, Fiebach H, Hertling I, Stein U, Kraft R, Desrosiers R. Biochemical and immunochemical characterization of structural proteins from retroviruses-D/New England and comparison to Mason-Pfizer monkey virus and permanent human fibroblast virus. Arch Virol 94:267-282, 1987 IF 1.498 Reviews: 16 (IF 54.022) 2016 Mudduluru G, Walther W, Kobelt D, Dahlmann M, Treese C, Stein U. Repositioning of drugs for intervention in tumor progression and metastasis: old drugs for new targets. Drug Resistance Updates, invited review, under review IF 9.121 2015 Böck BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human cancer. Cancer Res 74:4671-4675, 2014 IF 9.329 2013 Stein U. MACC1 - a novel target for solid cancers. Expert Opin Ther Targets 17:1039-1052, 2013 Editorial Highlight for September 2013 IF 4.901 Lemos C, Sack U, Schmid F, Juneja M, Stein U. Anti-metastatic treatment in colorectal cancer: Targeting signaling pathways. Curr Pharm Design 19:841-863, 2013 IF 3.288 2010 Stein U, Dahlmann M, Walther W MACC1 – more than metastasis? Facts and predictions about a novel gene. J Mol Med 88:11-18, 2010 IF 5.192 2009 Sack U, Stein U. Wnt up your mind – intervention strategies for S100A4-induced metastasis in colon cancer. Gen Physiol Biophys 28:F55-F64, 2009 IF 0.741 Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41:2356-2359, 2009 IF 4.887 Walther W, Stein U. Heat-responsive gene expression for gene therapy. Adv Drug Deliv Rev 61:641-649, 2009 IF 11.957 2006 Stein U, Walther W. Current Opinion: Reversal of ABC transporter-mediated multidrug resistance in cancer: A realistic option? Am J Cancer 5:285-297, 2006 Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences. Pädiatr Praxis 68:11-22, 2006 2005 Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences. Tägl Praxis 46:125-133, 2005 2004 Walther W, Stein U, Schlag PM. Gene therapy strategies for tumor diseases. Pädiatr Praxis 65:399-406, 2004 2003 Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences. Chirurg Praxis 62:215-223, 2003 8 Prof. Dr. Ulrike Stein Publication list 2002 Walther W, Stein U, Schlag PM. Gene therapy strategies for tumor diseases. Chirurg Praxis 60:19-26, 2002 2000 Stein U. Editorial. P-glycoprotein turned twenty: Are we any closer to fight drug resistance in cancer? Onkol 23:316-317, 2000 IF 0.640 Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60:249-271, 2000 IF 3.966 Books: 4 2015 Walther W, Stein U (editors) Gene therapy of solid cancers. Methods and protocols. Methods in molecular biology. ed. by Walther W, Stein U. Springer/Humana Press, New York, NY, 1-585, 2015. ISBN 978-1-4939-2726-5 2009 Walther W, Stein U (editors) Gene therapy of cancer: Methods and protocols. Methods in molecular biology. Springer/Humana Press, New York, NY, 1-717, 2009. ISBN 978-1-934115-85-5 2007 Schlag PM, Stein U (editors) Regional cancer therapy. Cancer drug discovery and development. Humana Press, Totowa, NJ, 1-455, 2007. ISBN 978-1-58829-672-6 2000 Walther W, Stein U (editors) Gene therapy of cancer: Methods and protocols. Methods in molecular medicine. Vol. 35 Humana Press, Totowa, NJ, 1-616, 2000. ISBN 0-89603-714-2 Book chapters: 22 2016 Mudduluru G, Ilm K, Dahlmann M, Stein U. MACC1, a novel player in solid cancer carcinogenesis. In: Molecular mechanisms in carcinogenesis ed. By Haybäck J. Springer, in press 2015 Dahlmann M, Stein U. RNA interference for antimetastatic therapy. In: Gene therapy of solid cancers. Methods and protocols. Methods in molecular biology. Vol. 1317. ed. by Walther W, Stein U. Springer/Humana Press, New York, NY, 153-165, 2015. ISBN 978-1-4939-2726-5 2013 Kobelt D, Aumann J, Schleef M, Schmeer M, Stein U, Schlag PM, Walther W. Minicircle-based vectors for non-viral gene therapy: in vitro characterization and in vivo application. In: Minicircle and Miniplasmid DNA vectors: The future of non-viral gene transfer ed. Schleef M. Wiley VCH Verlag; Weinhein, 177-188, 2013. ISBN 978-3-527-32456-9 9 Prof. Dr. Ulrike Stein Publication list 2012 Stein U. Gutartiges und bösartiges Wachstum von Säugerzellen: MACC1 – ein neu identifiziertes Gen ist ein Schlüsselmolekül für bösartiges Wachstum und Metastasierung. In: Nova Acta Leopoldina Vol. 393 eds. Wobus AM, Wobus U, Parthier B. Deutsche Akademie der Naturforscher Leopoldina, Halle/Saale, 101-114, 2012. ISBN 978-3-8047-3059-5 2011 Walther W, Schlag PM, Stein U. Local gene delivery for therapy of solid tumors. In: Drug delivery in oncology. From research concepts to cancer therapy. ed. Kratz F, Senter P, Steinhagen H. Wiley-VCH, Weinheim, 1391-1414, 2011. ISBN 978-3-527-32823-9 2010 Walther W, Stein U, Lage H. Jet-injection of short hairpin RNA-encoding vectors into tumor cells. In: RNA Therapeutics: Function, design, and delivery. Methods in molecular biology. Vol. 629 ed. by Sioud M. Springer/Humana Press, New York, NY, 121-137, 2010. ISBN 978-1-60761-656-6 2009 Walther W, Fichtner I, Schlag PM, Stein U. Nonviral jet-injection technology for intratumoral in vivo gene transfer of naked DNA. In: Gene therapy of cancer. Methods in molecular biology. Vol.542 ed. by Walther W, Stein U. Springer/Humana Press, New York, NY, 195-208, 2009. ISBN 978-1-934115-85-5 2008 Graschew G, Smith J, Rakowsky S, Roelofs TA, Schlag PM, Stein U. Improved tumor response by laser light treatment. In: Biophotonics. Photonic solutions for better healthcare. Vol. 6991 ed. by Popp J, Drexler W, Tuchin VV, Matthews DL. SPIE Publications, 69911A1-4, 2008. ISBN 978-0-819-47189-5 IF 0.2 Siegel R., Kobelt D, Knösel T, Stein U, Schlag PM, Walther W. Local nonviral intratumoral jet-injection gene transfer in metastatic melanoma and breast cancer: results of a phase I trial. In: Chir Forum. Vol. 37 ed. by Arbogast R, Schackert HK, Bauer H.. Springer-Verlag, Berlin, 131-132, 2008. ISBN 978-3-540-78821-8 2007 Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. In: Recent Results in Cancer Research – Targeted therapies in cancer. Vol. 176 ed. by Dietel M. Springer-Verlag, Heidelberg, 61-80, 2007. ISBN 978-3-540-46090-9 Stein U, Walther W, Schlag PM. Multidrug resistance - clinical implications for regional cancer therapy. In: Regional cancer therapy. Cancer drug discovery and development. ed. by Schlag PM, Stein U. Humana Press, Totowa, NJ, 3-18, 2007. ISBN 978-1-58829-672-6 Walther W, Stein U, Schlag PM. Local Gene Therapy for Cancer. In: Regional cancer therapy. Cancer drug discovery and development. ed by Schlag PM, Stein U. Humana Press, Totowa, NJ, 181-196, 2007. ISBN 978-1-58829-672-6 Siegel R, Stein U, Kobelt D, Aumann J, Schlag PM, Walther W. Early results of a phase-I-clinical trial of nonviral gene ransfer by jet-injection into cutaneous lesions of metastatic breast cancer and in-transit lesions of metastatic melanoma. In: Chir Forum. Vol. 36 ed. by Steinau HU, Schackert HK, Bauer H. Springer Verlag, Berlin, 441-443, 2007. ISBN 978-3-540-71122-3 10 Prof. Dr. Ulrike Stein Publication list 2006 Stein U. Multidrug resistance In: Encyclopedic reference of genomics and proteomics in molecular medicine. ed. by Ganten D, Ruckpaul K. Springer, Berlin Heidelberg New York,1208-1212, 2006. ISBN 3-540-44244-8 2005 Walther W, Stein U. Needleless jet-injection of naked DNA for nonviral in vivo gene transfer. In: DNA-Pharmaceuticals ed. by Schleef M. Wiley-VCH, Weinheim, 133-143, 2005. ISBN 3-527-31187-4 2000 Walther W, Stein U, Shoemaker RH, Schlag PM. Chemotherapy-inducible vector for gene therapy of cancer. In: Gene therapy of cancer: Methods and protocols. Methods in molecular medicine. Vol. 35 ed. by Walther W, Stein U. Humana Press, Totowa, NJ, 371-392, 2000. ISBN 0-89603-714-2 1998 Stein U, Walther W. Cytokine-mediated reversal of multidrug resistance. In: Multiple drug resistance in cancer 2. Molecular, Cellular and Clinical Aspects. ed. by Clynes M. Kluwer Academic Publishers, Dordrecht, 271-282, 1998. ISBN 0-7923-5272-6 Stein U, Walther W, Shoemaker RH, Schlag PM. IL-2 gene transfer for chemosensitization of human colon carcinoma cells. In: Advances in Experimental Medicine and Biology: Gene Therapy of Cancer. ed. by Walden P, Trefzer U, Sterry W, Farzaneh F. Plenum Publishing Corporation, London, 451:145-149, 1998. ISBN 978-0-306-46027-2 Uckert W, Walther W, Stein U. Large and small scale RNA preparations from eucaryotic cells. In: Methods in Molecular Biology: RNA isolation and characterization protocols. Vol. 86 ed. by Rapley R, Manning D. Humana Press,Totowa, NJ, 7-14, 1998. ISBN 978-0-89603-494-5 Walther W, Stein U, Fichtner I, Naundorf H, Alexander M, Shoemaker RH, Schlag PM. In vivo evaluation of a drug-inducible vector system for the combined gene and chemotherapy of cancer. In: Advances in Experimental Medicine and Biology: Gene Therapy of Cancer. Vol. 451 ed. by Walden P, Trefzer U, Sterry W, Farzaneh F. Plenum Publishing Corporation, London, 139-144, 1998. ISBN 978-0-306-46027-2 1996 Hoffmann J, Stein U, Schmidt-Peter P, Haensch W, Naundorf H, Scheper RJ, Fichtner I. Establishment and characterization of human sarcoma lines transplanted into nude mice. In: Immunodeficient animals: Models for cancer research. Vol. 51 ed. by Arnold W, Köpf-Maier P, Micheel B. Contrib Oncol Basel, Karger, 57-60, 1996. ISBN 978-3805562706 1994 Hoffmann J, Stein U, Schmidt-Peter P, Haensch W, Naundorf H, Fichtner I. Development and characterization of in vivo and in vitro tumor lines for investigation of the phenomenon of multidrug resistance in human sarcomas. In: Recent Advances in Chemotherapy. ed. by Einhorn J, Nord CE, Norrby SR. ASM Press, Washington DC, 885-887,1994. ISBN 978-1555810740 11 Prof. Dr. Ulrike Stein Statement Standing as a candidate for the Metastasis Research Society Board - Europe Herewith I would like to apply for the vacant position of a regular MRS Board Member, based in Europe, for a term of four years. Since the beginning of my occupational carrier, I am working in the field of translational oncology; in the first years, I focused on cancer drug resistance, its molecular mechanisms and circumvention/overcoming strategies. Since about 10 years, I concentrate my scientific efforts on research on metastasis of solid tumors. Metastatic dissemination of primary tumors is directly linked to patient survival and critically limits successful therapy in many tumor entities. Thus, the translational concepts of my group Translational Oncology of Solid Tumors aim at the identification of key molecules in tumor progression and metastasis for improved prognosis and therapy of solid cancers. In recent years, we newly discovered the previously undescribed gene MACC1 (metastasis-associated in colon cancer 1). MACC1 has been meanwhile acknowledged as prognostic and in part also as predictive biomarker for a broad variety of solid cancers by numerous other groups. We demonstrated MACC1, S100A4 and transcriptional targets or protein binding partners thereof as new diagnostic, prognostic and predictive key players for tumor progression and metastasis. Biomarker development was done in established and patient-derived 3D cultures, cell line-derived and patient-derived xenografts (PDX) and newly generated genetically engineered mouse models. We exploited this knowledge for improved disease prognosis and treatment response prediction in tissue and blood of cancer patients. Novel therapeutic approaches are currently tested in preclinical trials at the transcriptional, posttranscriptional, translational, post-translational and at the structural levels. Most promising strategies are currently being tested in clinical trials to treat patients with metastatic disease using small molecule inhibitors acting on these biomarkers. Thus, based on my scientific background, I would like to stand as a candidate for the Metastasis Research Society Board – Europe. Since the success of the MRS is strongly dependent on the active participation and time investment of the members of its executive board I understand the strong commitment which is expected to be provided by the board members. I would like to contribute to the enhancement of the visibility of the MRS, e.g. by pro-actively contributing in coordinating and organizing society activities to increase both the public awareness of the need for research on metastasis and the interdisciplinary networking of researchers and clinicians worldwide. Although our understanding of the biology of the metastatic process has certainly been improved in recent years, there are still ambitous challenges for e.g. signaling-driven interventions and their clinical translations desired. Thus, it would be very beneficial to initiate clinical trials focused on metastasis since although there is a decisive impact of the metastatic disease on cancer patient survival, clinical trials for new or repositioned anti-cancer/anti-metastatic drugs together with appropriate clinical trial designs are needed. Here, the involvement of clinicians and the pharmaceutical industry in the MRS is very welcome. Further, among all the points I would like to mention, I would like to focus on the official scientific journals of the MRS. It would be my pleasure to contribute to further improve the impact of these journals simultaneously reflecting the visibility of the MRS and the importance of research in the field of metastasis. Thereby, not only the knowledge will be spread, but also the number of new MRS members as well as of attracting young metastasis researchers might be increased. And certainly, I will take to chance to become an active part of the society`s Working groups. I am thankful and I feel honored for the possibility to apply to stand as a candidate for the Metastasis Research Society Board – Europe. I would like to express my willingness to support the MRS to increase its reputation and impact for better understanding metastasis as a biological process and for improved translation to better meet patients needs. 1